{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:22:26Z","timestamp":1791400946260,"version":"4.3.3"},"reference-count":36,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this article is to review abrocitinib, an oral Janus kinase (JAK) 1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A literature search of MEDLINE (PubMed) was performed for articles from inception through end-March 2022 using the following search terms: atopic dermatitis, abrocitinib, PF-04965842, methotrexate, cyclosporine, dupilumab, ruxolitinib, and JAK-STAT pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>English articles relating to pharmacology, pharmacokinetics, efficacy, and safety of abrocitinib, and other conventional systemic medications for AD, were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>Across phase IIb and phase III clinical trials, abrocitinib was efficacious with an average of 47.5% patients on 200 mg abrocitinib and 32.0% on 100 mg abrocitinib achieving an Investigator\u2019s Global Assessment (IGA) of 0 or 1 at 12 weeks. In comparison with dupilumab 300 mg subcutaneously every other week, patients on abrocitinib 200 mg once daily had improved disease severity and itch response. The majority of adverse events were not severe and self-limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>Prior to Food and Drug Administration (FDA) approval of abrocitinib, prednisone was the only FDA-approved oral medication for AD. Although biologics such as dupilumab have revolutionized care, some patients prefer oral medications. Compared with clinical trials of conventional AD treatments, abrocitinib appears more effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Abrocitinib is an efficacious oral JAK 1 inhibitor recently FDA-approved for patients \u2265 18 years old with moderate-to-severe AD who have not responded to systemic medications or when contraindicated otherwise.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221096713","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T06:53:58Z","timestamp":1652943238000},"page":"86-98","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":55,"title":["Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8507-8004","authenticated-orcid":false,"given":"Patrick O.","family":"Perche","sequence":"first","affiliation":[{"name":"Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8433-1653","authenticated-orcid":false,"given":"Madison K.","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Social Sciences &amp; Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000370220."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2023911."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417733460."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16900."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00548-6."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009."},{"key":"e_1_3_2_8_2","unstructured":"U.S. FDA Approves Pfizer\u2019s CIBINQO\u00ae (abrocitinib) for Adults with Moderate\u2014to\u2014Severe Atopic Dermatitis\u2014Pfizer. Accessed April 5 2022. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-cibinqor-abrocitinib-adults."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01598."},{"key":"e_1_3_2_10_2","unstructured":"Cibinqo (abrocitinib) [package insert]. New York NY: Pfizer Inc.; 2022. Accessed on April 5 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213871s000lbl.pdf."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218398."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S229667."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164080."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1546043."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1858."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13612."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-021-00745-6."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000725."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.075."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830."},{"key":"e_1_3_2_25_2","unstructured":"Reich K. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis who received background topical therapy in a 26-week randomized head-to-head trial [abstract no. D3T01.2B plus presentation]. In: European Academy of Dermatology and Venereology 30th Congress; Medicom. 2021. https:\/\/conferences.medicom-publishers.com\/wp-content\/uploads\/2021\/11\/LR-MCR-EADV-2021.pdf."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00618-3."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1832185."},{"key":"e_1_3_2_28_2","unstructured":"Dupixent (dupilumab) [package insert]. Tarrytown NY: Regeneron Pharmaceuticals Inc.; 2021. Accessed April 5 2022. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf."},{"key":"e_1_3_2_29_2","unstructured":"Rinvoq (upadacitinib) [package insert]. North Chicago IL: AbbVie Inc.; 2022. Accessed April 5 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211675s004lbl.pdf."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.682547."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.07.007."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085."},{"key":"e_1_3_2_33_2","unstructured":"GoodRx. Tofacitinib. Accessed February 6 2022. https:\/\/www.goodrx.com\/tofacitinib."},{"key":"e_1_3_2_34_2","unstructured":"Drugs.com. Dupixent Prices Coupons and Patient Assistance Programs. Accessed February 11 2022. https:\/\/www.drugs.com\/price-guide\/dupixent."},{"key":"e_1_3_2_35_2","unstructured":"GoodRx. Methotrexate. Accessed February 6 2022. https:\/\/www.goodrx.com\/methotrexate."},{"key":"e_1_3_2_36_2","unstructured":"GoodRx. Cyclosporine. Accessed February 6 2022. https:\/\/www.goodrx.com\/cyclosporine."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.05.004."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221096713","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221096713","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221096713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:51Z","timestamp":1777375011000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221096713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/10600280221096713"],"URL":"https:\/\/doi.org\/10.1177\/10600280221096713","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]}}}